Dynavax Technologies Corporation (DVAX) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Stock analysts at Cantor Fitzgerald began coverage on shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in a note issued to investors on Friday. The brokerage set an “overweight” rating and a $24.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 16.50% from the company’s current price.

DVAX has been the subject of several other research reports. Royal Bank Of Canada restated a “buy” rating and set a $26.00 price target on shares of Dynavax Technologies Corporation in a research note on Friday, September 1st. Cowen and Company restated an “outperform” rating and set a $45.00 price target on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. William Blair restated an “outperform” rating on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. ValuEngine lowered shares of Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research lowered shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $24.67.

Dynavax Technologies Corporation (NASDAQ:DVAX) opened at 20.60 on Friday. Dynavax Technologies Corporation has a 12 month low of $3.20 and a 12 month high of $21.85. The firm’s 50-day moving average price is $17.04 and its 200-day moving average price is $9.40. The firm’s market cap is $1.13 billion.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.15 million. During the same quarter last year, the business posted ($0.75) EPS. On average, equities research analysts expect that Dynavax Technologies Corporation will post ($1.58) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/09/15/dynavax-technologies-corporation-dvax-earns-overweight-rating-from-analysts-at-cantor-fitzgerald.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in DVAX. GMT Capital Corp grew its position in shares of Dynavax Technologies Corporation by 231.5% during the 1st quarter. GMT Capital Corp now owns 2,344,500 shares of the biopharmaceutical company’s stock valued at $13,950,000 after purchasing an additional 1,637,300 shares in the last quarter. PointState Capital LP purchased a new position in shares of Dynavax Technologies Corporation during the 2nd quarter valued at $13,510,000. Lord Abbett & CO. LLC purchased a new position in shares of Dynavax Technologies Corporation during the 2nd quarter valued at $7,777,000. Point72 Asset Management L.P. purchased a new position in shares of Dynavax Technologies Corporation during the 1st quarter valued at $4,323,000. Finally, Candriam Luxembourg S.C.A. purchased a new position in shares of Dynavax Technologies Corporation during the 2nd quarter valued at $5,066,000. Hedge funds and other institutional investors own 60.23% of the company’s stock.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply